ICON (NasdaqGS:ICLR) stock is in focus after its Q1 2026 earnings showed sales of US$2.03b, steady year on year, while net income and diluted EPS from continuing operations moved lower versus the prior period.

ICON's Q1 2026 results and commentary on margin pressure came alongside a sharp shift in sentiment, with a 1 month share price return of 41.38% and 3 month share price return of 57.68% contrasting with a year to date share price decline of 14.69% and a 3 year total shareholder return that is down 33.66%. This suggests short term momentum has picked up while longer term holders remain under water.

If ICON’s recent rebound has you reassessing opportunities in clinical research and AI, it can be useful to compare it with other healthcare companies applying AI to real world problems using the 39 healthcare AI stocks.

So with ICON trading around US$160.96, a roughly 31% discount to one intrinsic value estimate and below some analyst targets, is the recent rally just catching up, or is the market already pricing in future growth?

Most Popular Narrative: 5% Overvalued

At a last close of $160.96 versus a narrative fair value of $153.25, the current ICON price sits slightly above that widely followed estimate, setting up a debate around how much of the reset story is already reflected.

ICON's analyst fair value estimate has increased from $135.07 to $153.25 as analysts factor in the cleared accounting investigation, firm-wide resets to expectations, and ongoing strength in bookings and demand indicators across recent research updates.

Want to understand why ICON’s fair value moved higher despite lower recent margins and a reset year? The narrative leans on specific revenue trends, margin rebuild assumptions, and a future earnings multiple that has to compress meaningfully from today’s level. Curious which of those levers does the heavy lifting in the valuation model and how sensitive the outcome is if they shift even slightly.

Result: Fair Value of $153.25 (OVERVALUED)

However, that reset story around ICON also faces pressure from elevated trial cancellations and tighter biotech funding, which could weigh on bookings and delay any margin rebuild.

Another View: ICON Through a Cash Flow Lens

The fair value narrative puts ICON at about 5% overvalued versus $153.25, yet our DCF model tells a different story. With ICON trading around $160.96 and the SWS DCF model pointing to a future cash flow value of $231.72, the stock screens as materially undervalued on this method. Which yardstick do you trust more: earnings multiples or long term cash flows?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out ICON for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 43 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With sentiment on ICON still finely balanced between concern and cautious optimism, now is a good time to review the numbers yourself and weigh both sides of the story using the 2 key rewards and 2 important warning signs.

Looking for more investment ideas beyond ICON?

If ICON has sharpened your focus on quality and value, do not stop here. Broaden your watchlist with other stocks that fit clear, disciplined criteria.

• Target resilient businesses that may handle stress better than most by reviewing the 67 resilient stocks with low risk scores.
• Hunt for potentially mispriced opportunities by checking the 43 high quality undervalued stocks that combine strong fundamentals with appealing valuations.
• Spot companies that the market may be overlooking by scanning the screener containing 19 high quality undiscovered gems before everyone else starts paying attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.